Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Elaine Soliven, 24 Feb 2020
Administering intravenous propranolol hydrochloride does not reduce the duration of labour induction for nulliparous women who undergo vaginal delivery, according to a study presented at SMFM 2020.

Glecaprevir with pibrentasvir effective for genotype 1 HCV

06 Dec 2019

The combination of glecaprevir and pibrentasvir (G/P) may be a viable option for patients with genotype 1 hepatitis C virus (HCV) infection who had failed prior treatment with sofosbuvir and a nonstructural protein inhibitor, a new study has shown.

The phase IIIb, open label study included four groups: cirrhotic patients given G/P for 12 (group A; n=78; median age, 62 years; 82 percent male) or 16 (group B; n=49; median age, 62 years; 82 percent male) weeks, and patients with compensated cirrhosis who received G/P with ribavirin for 12 weeks (group C; n=21; median age, 60 years; 76 percent male) or G/P alone for 16 weeks (group D; n=29; median age, 64 years; 79 percent male). The primary outcome was sustained virologic response at 12 weeks (SVR12).

Majority of the participants achieved SVR12 (91.5 percent; n=162). The corresponding rates were 90 percent, 94 percent, 86 percent and 97 percent in groups A, B, C and D, respectively.

Twelve weeks of G/P led to an SVR12 rate of 89 percent, while extending treatment to 16 weeks improved the outcome to 95 percent. Treatment failure was reported in 13 patients with HCV genotype 1a.

G/P was “well tolerated” overall, such that there were no treatment discontinuations due to adverse events (AE) or abnormal laboratory findings. Around two-thirds of the participants experienced side effects, the most common of which were fatigue, nausea and headaches. Twelve serious AEs occurred in eight patients, one of which resulted in death.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Elaine Soliven, 24 Feb 2020
Administering intravenous propranolol hydrochloride does not reduce the duration of labour induction for nulliparous women who undergo vaginal delivery, according to a study presented at SMFM 2020.